Contents

Eplerenone for chronic central serous chorioretinopathy (VICI)

January 25, 2020

Clinical trial

Eplerenone for chronic central serous chorioretinopathy in patients with active, previously untreated disease for more than 4 months (VICI): a randomised, double-blind, placebo-controlled trial.

Lotery A, Sivaprasad S, O’Connell A, Harris RA, Culliford L, Ellis L, Cree A, Madhusudhan S, Behar-Cohen F, Chakravarthy U, Peto T, Rogers CA, Reeves BC.

Lancet. 2020 Jan 25;395(10220):294-303.
Full text | Metrics.

Main finding: Eplerenone did not significantly improve BCVA in chronic CSCR after 12 months of treatment.

 

  • Purpose: To to evaluate whether eplerenone was superior to placebo in terms of improving visual acuity in patients with chronic CSCR
  • Study type: Randomized controlled trial
  • Condition: Central Serous Chorioretinopathy

Participants: 18-60yo with treatment-naive CSCR for 4 months or more

 

  • n=114

 

Intervention:

 

Group 1: Eplerenone (25mg/day for 1 week, increasing to 50mg/day for up to 12 months) + usual care
Group 2: Placebo + usual care

 

NB: Usual care included PDT or subthreshold laser therap

Mean BCVA was 79.5 letters in the placebo group and 80.4 letters in the eplerenone group – adjusted estimated mean difference of 1.73 letters.

Share This Article :

Updated on March 7th, 2022

Source Archive

© 2024 - sourceshed